Sulfaphenazole: Benchmark CYP2C9 Inhibitor for Drug Metabolism and Antibacterial Research

Executive Summary: Sulfaphenazole (CAS No. 526-08-9) is a selective, competitive inhibitor of cytochrome P450 2C9 (CYP2C9), with an IC₅₀ of 0.63 μM in vitro, enabling precise modulation of drug metabolism (Chen et al., 2021). It demonstrates potent antibacterial activity against Mycobacterium tuberculosis, including XDR-TB strains, with minimum inhibitory concentrations (MICs) of 5.51–12.59 μg/mL, and exhibits low cytotoxicity (Vero cell IC₅₀ >64 μg/mL) (DOI). Sulfaphenazole is a reference tool for vascular endothelial function research, facilitating studies of oxidative stress and injury repair (Benchmark Article). The compound is insoluble in water, but highly soluble in DMSO and ethanol, and should be stored at -20°C for optimal stability (APExBIO).

Biological Rationale

Sulfaphenazole is a member of the sulfonamide class of antibiotics, originally developed for antibacterial therapy. Its clinical and research value arises from its dual activity: selectively inhibiting CYP2C9-mediated drug metabolism in mammalian systems and disrupting folic acid synthesis in bacteria (DOI). Inhibition of CYP2C9 is central to pharmacogenetic, drug-drug interaction, and adverse reaction studies, as this enzyme metabolizes a significant fraction of prescribed medications (Related Article). Sulfaphenazole’s robust antibacterial efficacy against M. tuberculosis, including XDR-TB, positions it as a lead compound for anti-tuberculosis drug development. In vascular biology, Sulfaphenazole is used to dissect the role of CYP2C-mediated oxidative stress in endothelial dysfunction, diabetic vascular complications, and tissue repair (Translational Key Article), extending the mechanistic insights available in prior reviews.

Mechanism of Action of Sulfaphenazole

• CYP2C9/CYP2C6 Inhibition: Sulfaphenazole acts as a competitive inhibitor at the CYP2C9 active site, with an IC₅₀ of 0.63 μM under standard in vitro conditions (DOI).
• Folic Acid Pathway Disruption in Bacteria: It inhibits bacterial dihydropteroate synthase (DHPS), blocking the synthesis of tetrahydrofolic acid crucial for bacterial viability.
• Antibacterial Selectivity: Sulfaphenazole demonstrates selective inhibition against M. tuberculosis H37Rv and XDR-TB strains, with MICs of 5.51 μg/mL (wild-type) and 12.59 μg/mL (XDR-TB) (DOI).
• Vascular and Oxidative Stress Modulation: In preclinical models, Sulfaphenazole inhibits CYP2C-mediated oxidative stress, restoring endothelium-dependent vasodilation and reducing ischemia-reperfusion injury (Benchmark Article).

Evidence & Benchmarks

• Sulfaphenazole inhibits CYP2C9 with an IC₅₀ of 0.63 μM in recombinant enzyme assays (Chen et al. 2021, DOI).
• It suppresses M. tuberculosis H37Rv with a MIC of 5.51 μg/mL, and XDR-TB with a MIC of 12.59 μg/mL under in vitro conditions (Chen et al. 2021, DOI).
• Low cytotoxicity is shown with Vero cell IC₅₀ >64 μg/mL (Chen et al. 2021, DOI).
• Effective in vivo dosing in mice is 5.13 mg/kg, administered intraperitoneally daily, improving vascular function and tissue repair (see Translational Review).
• Sulfaphenazole solutions are stable in DMSO (≥13.15 mg/mL) and ethanol (≥9.92 mg/mL with ultrasonication) (APExBIO).
• Recommended assay concentrations: 0.5–11.5 μM for CYP inhibition, 5–30 μg/mL for anti-tuberculosis studies, and 1–10 μM for cell function assays (APExBIO).

Applications, Limits & Misconceptions

Sulfaphenazole is a reference CYP2C9 inhibitor in drug metabolism studies, enabling the dissection of CYP2C9-mediated pharmacokinetics and drug-drug interaction risks. In vascular biology, it is used to probe oxidative stress pathways and endothelial dysfunction, particularly in models of diabetes and tissue injury. Its antibacterial profile supports research in tuberculosis, including drug-resistant strains. Compared to earlier reviews (Benchmark Article), this article provides updated quantitative thresholds and clarifies cytotoxicity boundaries.

Common Pitfalls or Misconceptions

• Sulfaphenazole is not effective against all bacterial species; its activity is primarily documented against M. tuberculosis and related mycobacteria.
• It is not a pan-CYP inhibitor; selectivity is high for CYP2C9 and CYP2C6, with minimal inhibition of other CYP isoforms.
• High concentrations (>30 μg/mL) may induce off-target effects in cellular assays not related to CYP2C9 inhibition.
• It does not reverse established antibiotic resistance mechanisms unrelated to folic acid pathway inhibition.
• Clinical use is historical; current applications are limited to laboratory and preclinical research.

Workflow Integration & Parameters

• Preparation: Dissolve Sulfaphenazole in DMSO (≥13.15 mg/mL) or ethanol (≥9.92 mg/mL with ultrasonication). The compound is insoluble in water (APExBIO).
• Storage: Store powder at -20°C. Solutions should be freshly prepared for short-term use only.
• CYP Inhibition Assays: Use at 0.5–11.5 μM for selective CYP2C9 inhibition in microsomal or recombinant systems.
• Antibacterial Assays: Apply 5–30 μg/mL concentrations for M. tuberculosis inhibition studies.
• In Vivo Dosing: Administer 5.13 mg/kg intraperitoneally daily in murine models for vascular function and injury repair research.
• Safety: Exhibits low cytotoxicity, but concentrations should be titrated according to cell type and endpoint.

For ordering and additional protocol details, see the Sulfaphenazole product page (C4131 kit, APExBIO).

Conclusion & Outlook

Sulfaphenazole remains a gold-standard selective CYP2C9 inhibitor and a benchmark reference for studies of drug metabolism modulation, vascular function, and antibacterial activity against M. tuberculosis. Its robust efficacy, low cytotoxicity, and defined selectivity profile make it indispensable in both pharmacogenetic and translational research. This article extends insight provided in previous reviews (see prior summary) by providing quantitative guidance and clarifying usage boundaries. As research evolves, new sulfonamide derivatives may further optimize antibacterial activity while minimizing CYP2C9 inhibition risk (DOI).